Pharmacokinetics of dolasetron following
โ
Ajit Shah; Robert Lanman; Vijay Bhargava; Scott Weir; William Hahne
๐
Article
๐
1995
๐
John Wiley and Sons
๐
English
โ 561 KB
Dolasetron, AnzemetTM, a 5-hydroxytryptamine receptor antagonist, is under investigation as an antiemetic agent. The keto-reduced metabolite of dolasetron has been identified in human plasma and is probably responsible for the majority of the antiemetic activity. This study evaluated the pharmacokin